Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

PYROTECH THERAPEUTICS

Request full access

Pyrotech is based on ground-breaking discoveries regarding ‘pyroptosis’, which is a type of cell death that controls infections by stimulating strong immune responses

ChinaFounded 2020Biotech & Life Sciences

About PYROTECH THERAPEUTICS

Pyrotech Therapeutics is a biopharmaceutical company established in October 2020, built upon foundational discoveries in pyroptosis, a type of inflammatory cell death critical to the immune response. The company was co-founded by Dr. Feng Shao, a leading academic from the National Institute of Biological Sciences, Beijing, whose research into the molecular mechanisms of pyroptosis has earned international recognition, including the 2022 William B. Coley Award. His scientific work laid the groundwork for the company's core mission. He is joined by co-founder and CEO Dr. TJ Deng, who brings drug development and corporate leadership experience to the venture.

The company's central focus is the modulation of the innate immune system by targeting pyroptosis. This biological process, while beneficial for fighting infections, can cause significant harm to organs when inappropriately activated. Pyrotech Therapeutics develops drug candidates that can either inhibit this pathway to treat inflammatory conditions or, conversely, amplify it within cancer cells to destroy tumors. The company's therapeutic targets include a wide range of inflammation-related diseases such as cancer, sepsis, and Alzheimer's disease. Its business model revolves around the discovery, development, and eventual commercialization of first-in-class small molecule and biologic immunomodulators.

Pyrotech has rapidly expanded its operational footprint, establishing a headquarters and small molecule development center in Beijing, a facility for bio-immune modulators in Shanghai, and a center for business development and clinical trials in the United States. Since its inception, the company has secured significant financing to advance its pipeline. A notable Series A round in July 2023 raised approximately $97 million, co-led by SDIC Venture Capital and China Venture Capital, among other investors. This was followed by a Series A+ round in May 2024. These funds are being used to push multiple drug candidates through the development process. The company's ALPK1 agonist, PTT-936, received FDA approval in November 2023 to begin clinical trials in the U.S. for tumor immunotherapy. Several other innate immune and pyroptosis inhibitors are also advancing toward clinical research.

Source: Dealroom company data

At a glance

Status
Operational
Employees
14
Open positions
None listed
Dealroom signal
81.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing May 2024 $28M $619M China Taiping Insurance · Lilly Asia Ventures · Frees Fund · Shunxi Private Equity Fund Management ↗
SERIES AOther financing Jul 2023 $96M $385M Frees Fund · Beijing Life Science Park Venture Capital · Taiping Medical and Health Industry Equity Investment Fund · MSA Capital ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

PYROTECH THERAPEUTICS website traffic

Latest recorded traffic for PYROTECH THERAPEUTICS is 750 monthly website visits, down 71.2% over the last three months. PYROTECH THERAPEUTICS's team grew 7.7% over the past year.

Latest monthly visits750 3-month web change-71.2% 1-year team growth+7.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

PYROTECH THERAPEUTICS in its local ecosystem

Live from Dealroom

The PYROTECH THERAPEUTICS office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

21 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed9 investors entered at this stage

  • MSA Capital
  • Lilly Asia Ventures
  • Frees Fund
  • QingLan Fund
  • Beijing Life Science Park Venture Capital
  • Zhongguancun Development Group
  • BioTrack Capital
  • Chang Development
  • Qisheng Capital

Series A11 investors entered at this stage

  • Taiping Medical and Health Industry Equity Investment Fund
  • Hetang Venture Capital Management (Beijing)
  • SDIC Venture Capital
  • China Ventures Fund
  • China Life Investment Management
  • China Taiping Insurance
  • Shunxi Private Equity Fund Management
  • Beijing Medical Fund
  • Function Capital
  • Baheal Pharmaceutical
  • China Venture Capital Fund

Other known investors1 additional known investor

  • National Institute of Biological Sciences (NIBS), Beijing.
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See PYROTECH THERAPEUTICS’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.